Establishment of a structure-activity relationship of the 1H-imidazo[4,5-c]quinoline-based kinase inhibitor NVP-BEZ235 as a lead for African sleeping sickness
MetadataShow full item record
Altmetrics Handle Statistics
Altmetrics DOI Statistics
The compound NVP-BEZ235 (1) is a potent inhibitor of human phospoinositide-3-kinases (PI3Ks) and mammalian target of rapamycin (mTOR) that also showed high inhibitory potency against T. brucei cultures. With an eye towards using 1 as a starting point for anti-trypanosomal drug discovery, we report efforts to reduce host cell toxicity, improve the physicochemical properties and improve the selectivity profile over human kinases. In this work we have developed structure-activity relationships (SAR) for analogs of 1 and have prepared analogs of 1 with improved solubility properties and good predicted central nervous system exposure. In that way, we have identified 4e, 9, 16e and 16g as the most promising leads to date. We also report cell phenotype and phospholipidomic studies that suggest that these compounds exert their anti-trypanosomal effects, at least in part, by inhibition of lipid kinases.
Seixas , J D , Luengo-Arratta , S A , Diaz , R , Saldivia , M , Rojas-Barros , D I , Manzano , P , Gonzalez , S , Berlanga , M , Smith , T K , Navarro , M & Pollastri , M P 2014 , ' Establishment of a structure-activity relationship of the 1H-imidazo[4,5-c]quinoline-based kinase inhibitor NVP-BEZ235 as a lead for African sleeping sickness ' , Journal of Medicinal Chemistry , vol. 57 , no. 11 , pp. 4834-4848 . https://doi.org/10.1021/jm500361r
Journal of Medicinal Chemistry
© 2014 American Chemical Society. This is an article distributed in accordance with the terms of the Creative Commons Attribution (CC BY NC 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for noncommercial use, provided the original work is properly cited.
Items in the St Andrews Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.